These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33533650)

  • 1. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
    Sarkis J; Khalil N; Alkassis M
    Future Oncol; 2021 Mar; 17(9):991-992. PubMed ID: 33533650
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2016 Jul; 58(1499):e97. PubMed ID: 27403787
    [No Abstract]   [Full Text] [Related]  

  • 4. Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor.
    Gebrael G; Jo Y; Mathew Thomas V; Li H; Sayegh N; Tripathi N; Srivastava A; Nordblad B; Dal E; Narang A; Brundage J; Campbell P; Galarza Fortuna G; Hage Chehade C; Maughan BL; Agarwal N; Swami U
    Cancer; 2024 Aug; 130(15):2621-2628. PubMed ID: 38564301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
    Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib approved for first-line treatment of advanced renal cell carcinoma.
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):96. PubMed ID: 29741507
    [No Abstract]   [Full Text] [Related]  

  • 7. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma].
    Naoun N; Vano YA
    Bull Cancer; 2021 Nov; 108(11):991-993. PubMed ID: 34538614
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
    Roviello G; Generali D
    Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
    Santini D; Stellato M; De Giorgi U; Pantano F; De Lisi D; Casadei C; Maruzzo M; Bimbatti D; Naglieri E; Buti S; Bersanelli M; De Vivo R; Di Lorenzo G; Sbrana A; Verzoni E; Soraru' M; Fornarini G; Mucciarini C; Grillone F; Mini E; Vignani F; Attademo L; Pignata S; Procopio G
    Am J Clin Oncol; 2021 Mar; 44(3):121-125. PubMed ID: 33617179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
    Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
    J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
    Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
    Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
    [No Abstract]   [Full Text] [Related]  

  • 13. Cabozantinib improves clinical outcomes in renal cancer.
    Das M
    Lancet Oncol; 2017 Jan; 18(1):e2. PubMed ID: 27890466
    [No Abstract]   [Full Text] [Related]  

  • 14. Cabozantinib in renal cell carcinoma: only a METEOR or a rising star?
    Bersanelli M; Buti S
    Acta Biomed; 2016 Sep; 87(2):224-5. PubMed ID: 27649009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib use in renal cell carcinoma.
    Neuwelt AJ; Mathur S; Johnson AT; Kessler ER; Bowles DW
    Drugs Today (Barc); 2017 May; 53(5):299-307. PubMed ID: 28650002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?
    Ciccarese C; Massari F; Tortora G
    Eur Urol; 2016 May; 69(5):969-70. PubMed ID: 26724839
    [No Abstract]   [Full Text] [Related]  

  • 18. Cabozantinib Approved for Renal Cell Carcinoma.
    Cancer Discov; 2016 Jun; 6(6):OF3. PubMed ID: 27150533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
    Abdelaziz A; Vaishampayan U
    Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial.
    Rosellini M; Tassinari E; Marchetti A; Mollica V; Massari F
    Eur Urol; 2024 Jan; 85(1):97-98. PubMed ID: 37777426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.